Albany, NY, May 11, 2015 (GLOBE NEWSWIRE) -- Rising incidence of human papillomavirus (HPV) infections in developing as well as underdeveloped economies and increased seroprevalence have respectively driven the global human papillomavirus and cytomegalovirus therapeutics market over recent years, states a recently published report by Transparency Market Research. The report is titled "Human Papillomavirus and Cytomegalovirus Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" and is available for sale on the company website.According to the research report, the global HPV therapeutics market was worth US$1.40 billion in 2013 and is projected to be worth US$2.34 billion in 2020, growing at a 7.7% CAGR during the report's forecast period of 2014 to 2020. The CMV therapeutics market, on the other hand, stands to grow from US$0.87 billion in 2013 to US$0.92 billion in 2020 at a meager CAGR of 1.5% between 2014 and 2020.
Browse Full Market Research of Human Papillomavirus and Cytomegalovirus Therapeutics Market With ToC & Free Analysis: http://www.transparencymarketresearch.com/hpv-cmv-therapeutics-market.html
The HPV therapeutics market is segmented on the basis of drug class, application, and pipeline drugs. In terms of revenue, immunomodulators were the dominant drug class in 2013 owing to cost-effectiveness, increased efficiency, and its nature as a non-invasive treatment. Application-wise, the segment of genital warts held the largest share of the HPV therapeutics market that year.Application, antiviral drugs, and pipeline drugs are the criteria based on which the CMV therapeutics market is segmented. Among the major antiviral drugs, ganciclovir and valganciclovir held the largest share of the CMV therapeutics market in 2013, while retinitis was the biggest application segment of the CMV therapeutics market that year.
Browse Press Release of Human Papillomavirus and Cytomegalovirus Therapeutics Market: http://www.transparencymarketresearch.com/pressrelease/hpv-cmv-therapeutics-market.htm
The global HPV and CMV therapeutics market is segmented into five major regions:
- North America
- South America
- Europe
- Asia Pacific
- Rest of the World
Get Sample Report Copy OR For further inquiries, click here: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3986
North America led the global HPV and CMV therapeutics market in 2013 in term of revenue. The HPV market in the region is driven by a rise in the sexually active population, increase in diagnostic rate, and growing international migration. The CMV therapeutics market in North America is fueled by increasing cost of drugs, rise in organ transplant surgeries, and high risk of STDs. The South America and Asia Pacific region are both estimated to witness significant growth in the HPV and CMV therapeutics market by 2020.
Other Reports Published by Transparency Market Research :
- Meningococcal Vaccines Market: http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html
- Peptide Therapeutics Market: http://www.transparencymarketresearch.com/peptide-therapeutics-market.html
Clinigen Group plc, Perrigo Company plc, Roche Holdings AG, Merck & Co., Inc., AbbVie, Inc., Actavis plc, and Valeant Pharmaceuticals International, Inc. are the companies profiled in the HPV and CMV therapeutics market report. The CMV therapeutics market was dominated by Roche AG in 2013, thanks to Valcyte being the sole branded formulation available in the market. The HPV therapeutics market was led by Valeant Pharmaceuticals in 2013, owing to the success of its leading brands Aldara, Zyclara, Efudex, and Carac.Each of the players featured in this report are profiled based on attributes such as company and financial overview, product portfolio, recent developments, and business strategies such as mergers and acquisitions, geographic expansions, R&D practices, collaborations and agreements, and product launches.
Browse All Pharmaceuticals Market Research Reports: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About Us :
Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.